Clinical trial · people
Retatrutide 12 mg: UACR 37.0% lower vs placebo in type 2 diabetes
Checked against the paper Clinical trialPublished by PepVault
The takeaway
In these trials, higher retatrutide doses were linked to less albumin in the urine, and to higher eGFR in people with obesity but not in people with type 2 diabetes, in groups where most started with normal albumin levels.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2025
- Journal
- Kidney Int Rep
What they tested
The team wanted to know how retatrutide changes kidney measures in people with type 2 diabetes, or with overweight or obesity.
How the study was done
A post hoc analysis, meaning one planned after the fact, of 2 placebo-controlled trials with doses from 0.5 to 12 mg: 281 people with type 2 diabetes over 36 weeks, with a dulaglutide 1.5 mg comparison group, and 338 people with overweight or obesity but no diabetes over 48 weeks. Everyone had an eGFR (a measure of how well the kidneys filter blood) of at least 45 ml/min per 1.73 m2.

Model. Individual results vary.
What they found
In people with type 2 diabetes, the 12 mg arm had UACR (the urine albumin-to-creatinine ratio, a measure of albumin in the urine) 37.0% lower than placebo at 36 weeks (95% CI: -57.3 to -7.0), while eGFR did not change compared with placebo. In people with overweight or obesity, UACR was 28.0% lower in the 8 mg arm and 31.5% lower in the 12 mg arm than placebo at 48 weeks. In that group, eGFR based on creatinine rose by 5.3 ml/min per 1.73 m2 in the 8 mg arm and 8.5 ml/min per 1.73 m2 in the 12 mg arm, and eGFR based on cystatin C, or on both markers combined, rose by a similar amount.
What it doesn’t show
This was a post hoc analysis, and most people started with normal albumin levels (median UACR of 13 mg/g and 7 mg/g), so the drop in actual albumin amounts was modest. People with eGFR below 45 were not included.
The paper
Heerspink et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney Int Rep. 2025.
The compound
More studies on Retatrutide
- Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysisMeta-analysis · people · 2026
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: HbA1c down up to 1.94% in TRANSCEND-T2D-1Randomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.